Moderna (MRNA) closed at $34.01 in the latest trading session, marking a -1.9% move from the prior day. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

A lot can happen in 10 years, and that's good news for a struggling stock like Moderna (NASDAQ: MRNA).Once a stock market star generating billions of dollars in coronavirus vaccine revenue ...

Moderna’s stock remains far below its 52-week high of $170.47 and is down more than 65% over the past year. ... less of a roller-coaster ride as evident in HQ Portfolio performance metrics.

In the latest trading session, Moderna (MRNA) closed at $27.19, marking a -0.75% move from the previous day. This change lagged the S&P 500's 0.74% gain on the day. On the other hand, the Dow ...

Moderna’s stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective cut by analysts at Morgan Stanley from $39.00 to $32.00 in a research report issued on Wednesday,Benzinga reports.

Moderna said the FDA approved its new COVID-19 vaccine "for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor." ...

Moderna Inc. MRNA is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 months ...